Prevalence of multidrug resistant and extended spectrum beta-lactamase producing Pseudomonas aeruginosa in a tertiary care hospital

Abstract EN

Resistance to broad-spectrum beta-lactams, mediated by extended-spectrum betalactamase enzymes (ESBL), is an increasing problem worldwide.

The present study was undertaken to determine the incidence of ESBL-production among the clinical isolates of Pseudomonas aeruginosa and their susceptibility to selected antimicrobials.

A total of one eighty-seven clinical specimens were tested for the presence of ESBL production using the double-disc synergy test.

Of these, 25.13 % (n = 47) isolates of P.

aeruginosa were observed as ESBL positive.

The maximum number of ESBL-producing strains were found in sputum (41.67 % ; n = 24) followed by pus (28.36 % ; n = 19), cerebrospinal fluid and other body fluids (21.74 % ; n = 5), urine (20.45 % ; n = 9) and blood (13.79 % ; n = 4).

ESBL producing isolates exhibited co-resistance to an array of antibiotics tested.

Imipenem and meropenem can be suggested as the drugs of choice in our study.